Intracranial PrEssure Time dOse (ImPETO)
The new Integra CereLink ICP monitor integrate the possibility of recording and displaying continuously the AUC (Pressure Time Dose, PTD) and other ICP derived variables and provide the possibility of evaluating the utility of this information at the bedside. It offers the opportunity to test in a standardized way the clinical value of the PTD computation in this setting. Therefore, this study aims to test clinically if PTD recorded continuously is associated to patients' outcome and to identify a threshold of…
Conditions studied
Intracranial Hypertension, Traumatic Brain Injury, Subarachnoid Hemorrhage, Intracranial Hemorrhages
About this study
The new Integra CereLink ICP monitor integrate the possibility of recording and displaying continuously the AUC (Pressure Time Dose, PTD) and other ICP derived variables and provide the possibility of evaluating the utility of this information at the bedside. It offers the opportunity to test in a standardized way the clinical value of the PTD computation in this setting. Therefore, this study aims to test clinically if PTD recorded continuously is associated to patients' outcome and to identify a threshold of PTD associated with the transition from good to negative outcomes.
Interventions
- Procedure: intracranial pressure monitoring — Invasive monitoring of intracranial pressure by using CereLink monitor.
Primary outcomes
- Association between PTD and in-hospital mortality. (12 months)
Eligibility information
Study locations
- Fondazione IRCCS San Gerardo dei Tintori, Monza, MB 20900 Italy
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.